Clinical Trial Update: Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating utomilumab and ISA101b vaccination in HPV-16–positive incurable oropharyngeal cancer; the study was terminated with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
• Malignant Neoplasms of Lip Oral Cavity and Pharynx
• Oropharyngeal Cancer

Drugs mentioned

• ISA101b (ISA101b)
• Utomilumab (utomilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx | Phase 2 | Status: TERMINATED | Results posted: 2022-12-16